Shandong Kexing Bioproducts Co. Ltd. A

Kexing Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company of 134 million yuan. The company's total operating revenue was 607 million yuan, down 13.33% from the same period last year. Net cash inflow from operating activities was 25.2456 million yuan, down 15.28% year-on-year. The company's latest asset-liability ratio was 50.49%, gross margin was 54.10%, and diluted earnings per share was 0.68 yuan.

Kexing Biopharm released its 2026 interim report, with net profit attributable to the parent up 66.7% year on year to 134 million yuan. Operating revenue was 607 million yuan, down 13.3% year on year; net profit attributable to the parent excluding non-recurring items was a loss of 78.36 million yuan, down 273.1% year on year. Second-quarter net profit attributable to the parent was 152 million yuan, up 177.3% year on year. The company said the decline in operating revenue was mainly affected by intensifying competition at home and abroad, the expansion of volume-based procurement, and changes in value-added tax policy, while research and development expenses rose 24.40% year on year and foreign exchange losses increased significantly.